Galvin Gaustad & Stein LLC Has $9.35 Million Stock Position in United Therapeutics Co. (NASDAQ:UTHR)

Galvin Gaustad & Stein LLC lifted its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 6.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 26,512 shares of the biotechnology company’s stock after purchasing an additional 1,505 shares during the quarter. Galvin Gaustad & Stein LLC owned approximately 0.06% of United Therapeutics worth $9,354,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of UTHR. Envestnet Asset Management Inc. grew its stake in United Therapeutics by 12.7% in the 2nd quarter. Envestnet Asset Management Inc. now owns 48,981 shares of the biotechnology company’s stock valued at $15,603,000 after buying an additional 5,531 shares during the last quarter. Benjamin F. Edwards & Company Inc. grew its position in United Therapeutics by 14.0% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 343 shares of the biotechnology company’s stock worth $109,000 after purchasing an additional 42 shares during the last quarter. Ensign Peak Advisors Inc grew its position in United Therapeutics by 27.2% in the 2nd quarter. Ensign Peak Advisors Inc now owns 33,677 shares of the biotechnology company’s stock worth $10,728,000 after purchasing an additional 7,205 shares during the last quarter. 1832 Asset Management L.P. acquired a new stake in United Therapeutics in the 2nd quarter worth $1,562,000. Finally, Evergreen Capital Management LLC acquired a new stake in United Therapeutics in the 2nd quarter worth $375,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR opened at $370.00 on Thursday. United Therapeutics Co. has a one year low of $208.62 and a one year high of $417.82. The company has a 50 day moving average of $365.33 and a 200-day moving average of $355.12. The stock has a market cap of $16.52 billion, a price-to-earnings ratio of 16.25, a P/E/G ratio of 0.94 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.16 by $0.23. The firm had revenue of $748.90 million during the quarter, compared to analysts’ expectations of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The business’s revenue for the quarter was up 22.9% on a year-over-year basis. During the same quarter in the previous year, the company earned $5.38 earnings per share. Equities research analysts anticipate that United Therapeutics Co. will post 25.22 earnings per share for the current year.

Insider Activity at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 10,000 shares of the company’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $364.91, for a total transaction of $3,649,100.00. Following the sale, the chief operating officer now directly owns 2,577 shares of the company’s stock, valued at approximately $940,373.07. This represents a 79.51 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO James Edgemond sold 7,800 shares of the company’s stock in a transaction on Monday, October 28th. The stock was sold at an average price of $350.00, for a total transaction of $2,730,000.00. Following the sale, the chief financial officer now directly owns 6,978 shares in the company, valued at $2,442,300. This trade represents a 52.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 146,848 shares of company stock worth $55,165,099. 11.90% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on UTHR shares. Oppenheimer raised their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, October 31st. StockNews.com raised shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, January 16th. LADENBURG THALM/SH SH raised their price objective on shares of United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. HC Wainwright raised their price objective on shares of United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Finally, TD Cowen raised their price objective on shares of United Therapeutics from $350.00 to $400.00 and gave the stock a “buy” rating in a report on Monday, October 21st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $378.36.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.